This study is being done to determine the safety and outcome (long-term control) of a
high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem
cells from a partially matched adult family member donor, called haploidentical stem cell
transplantation, in high-risk sickle cell disease patients.
Funding Source - FDA OOPD